共 50 条
- [21] Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Goodman, Rachel S.Lawless, AleighaWoodford, RachelFa'ak, FaisalTipirneni, AshaPatrinely, James RandallYeoh, Hui-LingRapisuwon, SutheeHaydon, AndrewOsman, ImanMehnert, Janice M.Long, Georgina V.Sullivan, Ryan J.Carlino, Matteo S.Menzies, Alexander M.Johnson, Douglas Buckner
- [22] Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective studyECLINICALMEDICINE, 2023, 59Wang, XiaoyuCang, WeiLiu, XiaomeiCheng, YuWan, XirunFeng, FengzhiRen, TongZhao, JunJiang, FangCheng, HongyanGu, YuChen, LihuaLi, ChenLi, XiuqinYang, JunjunLu, XinXiang, Yang
- [23] Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyANNALS OF ONCOLOGY, 2020, 31 (08) : 1075 - 1082Owen, C. N.Shoushtari, A. N.Chauhan, D.Palmieri, D. J.Lee, B.Rohaan, M. W.Mangana, J.Atkinson, VZaman, F.Young, A.Hoeller, C.Hersey, P.Dummer, R.Khattak, M. A.Millward, M.Patel, S. P.Haydon, A.Johnson, D. B.Lo, S.Blank, C. U.Sandhu, S.Carlino, M. S.Larkin, J. M. G.Menzies, A. M.Long, G., V
- [24] Clinical outcomes after adjuvant anti-PD1 therapy for high-risk resectable melanoma and predictors of responseJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Marsiglio, JohnBingjian, FengKovacsovics, MagdalenaGibson, BeritZhou, QinSwami, UmangRussell, Jeffery ScottErickson-Wayman, AlyssaAsare, Elliot AmponsahMonroe, MarcusBowles, Tawnya LynnNix, DavidWilliams, MatthewTan, Aik-choonHyngstrom, John RobertHu-Lieskovan, Siwen
- [25] Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapyEUROPEAN JOURNAL OF CANCER, 2024, 212Woodford, RachelMcKeown, JanetHoeijmakers, Lotte L.Mangana, JohannaDimitriou, FlorentiaAllayous, ClaraZaman, FarzanaAya, FranciscoMarsiglio, JohnGoodman, RachelRayson, VictoriaPlaczke, JoannaKessels, JolienRamalyte, EgleHaque, WaqasWilson, IsabellaTrojaniello, ClaudiaBenannoune, NaimaRoberts-Thomson, RachelRobert, CarolineBlank, Christian U.Dummer, ReinhardLebbe, CelesteHaydon, AndrewArance, AnaHu-Lieskovan, SiwenJohnson, Douglas B.Mcarthur, Grant A.Rutkowski, PiotrNeyns, BartSullivan, Ryan J.Weber, JeffreyCarlino, Matteo S.Ascierto, Paolo A.Lo, SerigneLong, Georgina, VMenzies, Alexander M.
- [26] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesBRITISH JOURNAL OF CANCER, 2017, 116 (12) : 1558 - 1563Parakh, SagunPark, John J.Mendis, SheharaRai, RajatXu, WenLo, SerigneDrummond, MartinRowe, CatherineWong, AnnieMcArthur, GrantHaydon, AndrewAndrews, Miles C.Cebon, JonathanGuminski, AlexKefford, Richard F.Long, Georgina V.Menzies, Alexander M.Klein, OliverCarlino, Matteo S.
- [27] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesANNALS OF ONCOLOGY, 2016, 27Park, J. J.Parakh, S.Mendis, S.Rai, R.Lo, S.Haydon, A.Andrews, M. C.Cebon, J.Guminski, A.Kefford, R.Long, G. V.Menzies, A. M.Klein, O.Carlino, M. S.
- [28] Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesBritish Journal of Cancer, 2017, 116 : 1558 - 1563Sagun ParakhJohn J ParkShehara MendisRajat RaiWen XuSerigne LoMartin DrummondCatherine RoweAnnie WongGrant McArthurAndrew HaydonMiles C AndrewsJonathan CebonAlex GuminskiRichard F KeffordGeorgina V LongAlexander M MenziesOliver KleinMatteo S Carlino
- [29] The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy (vol 32, 440, 2015)MEDICAL ONCOLOGY, 2015, 32 (03)Akman, TulayOztop, IlhanBaskin, YaseminAkbarpour, MahdiUnal, Olcun UmitOflazoglu, UtkuEllidokuz, HulyaLebe, Banu
- [30] Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma (vol 7, pg 744, 2021)JAMA ONCOLOGY, 2021, 7 (05) : 785 - 785Patrinely, J. R., Jr.Johnson, R.Lawless, A. R.